Edition:
United Kingdom

Sorrento Therapeutics Inc (SRNE.OQ)

SRNE.OQ on NASDAQ Stock Exchange Capital Market

6.18USD
6:27pm BST
Change (% chg)

$0.08 (+1.23%)
Prev Close
$6.10
Open
$6.15
Day's High
$6.25
Day's Low
$6.07
Volume
107,534
Avg. Vol
758,803
52-wk High
$10.65
52-wk Low
$1.50

Chart for

About

Sorrento Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, acquisition, development and commercialization of drug therapeutics. Its primary therapeutic focus is oncology, including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications,... (more)

Overall

Beta: 1.68
Market Cap(Mil.): $137.77
Shares Outstanding(Mil.): 76.54
Dividend: --
Yield (%): --

Financials

  SRNE.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -0.64 -- --
ROI: -12.13 1.58 14.38
ROE: -29.69 2.41 16.07

BRIEF-Sorrento Therapeutics Announces Unsecured $120.5M Convertible Note Financing

* SORRENTO THERAPEUTICS ANNOUNCES UNSECURED $120.5M CONVERTIBLE NOTE FINANCING

27 Mar 2018

BRIEF-Sorrento Therapeutics Files ‍Prospectus Related To Offering

* SORRENTO THERAPEUTICS INC FILES ‍PROSPECTUS RELATED TO OFFERING OF UP TO 1.4 MILLION SHARES CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING Source text: (https://bit.ly/2IFWs1n) Further company coverage:

22 Mar 2018

BRIEF-Sorrento Therapeutics Files ‍Prospectus Related To Offering

* SORRENTO THERAPEUTICS INC FILES ‍PROSPECTUS RELATED TO OFFERING OF UP TO 34.2 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING Source text: (https://bit.ly/2pwUPvb) Further company coverage:

22 Mar 2018

BRIEF-Sorrento Therapeutics Welcomes Jiong Shao As Chief Financial Officer

* SORRENTO THERAPEUTICS WELCOMES JIONG SHAO AS CHIEF FINANCIAL OFFICER AND REAFFIRMS INTENT TO SEEK NASDAQ/HKSE DUAL LISTING IN 2018

19 Mar 2018

BRIEF-Sorrento Says Its CAR-T Cell Therapy Showed Therapeutic Activity In Stage IV Pancreas Cancer In Early Stage Trial

* SORRENTO THERAPEUTICS AUTOLOGOUS ANTI-CEA CAR-T CELL THERAPY FOR LIVER METASTASES DEMONSTRATES THERAPEUTIC ACTIVITY IN STAGE IV PANCREAS CANCER IN A PHASE 1B HITM-SURE TRIAL (NCT02850536) Source text for Eikon: Further company coverage:

05 Mar 2018

FDA approves Sorrento's non-opioid painkiller patch, shares jump

Sorrento Therapeutics Inc said on Wednesday the U.S. Food and Drug Administration has approved ZTlido, its non-opioid painkiller patch for nerve pain related to shingles, which it plans to launch later this year.

28 Feb 2018

UPDATE 2-FDA approves Sorrento's non-opioid painkiller patch, shares jump

* To compete with Endo's Lidoderm, generics (Adds background, company and analyst comments)

28 Feb 2018

BRIEF-Sorrento Therapeutics' Unit Receives FDA Approval For Non-Opioid Ztlido

* SORRENTO THERAPEUTICS SUBSIDIARY, SCILEX, RECEIVES US FDA APPROVAL FOR NON-OPIOID ZTLIDO™ (LIDOCAINE TOPICAL SYSTEM) 1.8% FOR PHN PAIN

28 Feb 2018

FDA approves Sorrento's painkiller patch

Feb 28 The U.S. Food And Drug Administration on Wednesday approved Sorrento Therapeutics Inc's ZTlido, a stick-on patch to treat nerve pain due to shingles.

28 Feb 2018

BRIEF-Sorrento Therapeutics- Audit Committee Concluded Co's Financial Statements For 3 & 9 Months Ended Sept 30, 2017 Should Not Be Relied Upon​

* SORRENTO THERAPEUTICS - ‍ON FEB 26, AUDIT COMMITTEE CONCLUDED CO'S FINANCIAL STATEMENTS FOR 3 & 9 MONTHS ENDED SEPT 30, 2017 SHOULD NOT BE RELIED UPON​

27 Feb 2018

Earnings vs. Estimates